Alekshun Michael N
Paratek Pharmaceuticals, Inc., 75 Kneeland Street, Boston, MA 02111, USA.
Expert Opin Investig Drugs. 2005 Feb;14(2):117-34. doi: 10.1517/13543784.14.2.117.
The development of new antibiotics is crucial to controlling current and future infectious diseases caused by antibiotic-resistant bacteria. Increased development costs, the difficulty in identifying new drug classes, unanticipated drug toxicities, the ease by which bacteria develop resistance to new antibiotics and the failure of many agents to address antibiotic resistance specifically, however, have all led to an overall decline in the number of antibiotics that are being introduced into clinical practice. Although there are few, if any, advances likely in the immediate future, there are agents in both clinical and preclinical development that can address some of the concerns of the infectious disease community. Many of these antibiotics will be tailored to specific infections caused by a relatively modest number of susceptible and resistant organisms.
开发新型抗生素对于控制当前及未来由耐药菌引起的传染病至关重要。然而,研发成本增加、确定新型药物类别存在困难、出现意外的药物毒性、细菌对新型抗生素产生耐药性的容易程度以及许多药物未能专门解决抗生素耐药性问题,所有这些都导致引入临床实践的抗生素数量总体下降。尽管在不久的将来可能几乎没有进展,但临床和临床前研发中都有一些药物可以解决传染病界的一些担忧。这些抗生素中的许多将针对由相对少量的敏感菌和耐药菌引起的特定感染。